How close are miRNAs from clinical practice? A perspective on the diagnostic and therapeutic market

The discovery of miRNAs in the mid-90s has changed the dogma of gene expression regulation. Currently, miRNAs are the main theme of thousands of publications each year and their involvement in human diseases is everyday more deeply understood. With that being known, what are the actual clinical applications of miRNAs and how far are they truly from the patients? To address this question, we reviewed the miRNA diagnostic and therapeutic market. With many companies developing miRNA panels, the activity is high in the diagnostic area. Some products, notably for thyroid cancer (Interpace Diagnostic), are already available to clinician and covered by major insurance companies. In comparison, the therapeutic market, mainly driven by miRNA mimics and antagomiR products, is less advanced. Miravirsen (produced by Roche/Santaris) and RG-101 (produced by Regulus Therapeutics), designed to treat hepatitis C, are considered the flagship products of this class of future drugs. All of the miRNA-based drugs are currently in clinical trials and none have yet reached the pharmaceutical breakthrough. However, acquisition of miRNA-based companies by major pharmas is sending a positive feedback on their potentials. With multiple initiatives on their way, the next years will definitely be determinant for the miRNA market that is still in his infancy.

[1]  A. Jackson,et al.  A MicroRNA-29 Mimic (Remlarsen) Represses Extracellular Matrix Expression and Fibroplasia in the Skin. , 2019, The Journal of investigative dermatology.

[2]  M. A. Fara,et al.  A PCR-free technology to detect and quantify microRNAs directly from human plasma. , 2018, The Analyst.

[3]  D. Kessler,et al.  Age- and sex-dependent changes in levels of circulating brain-enriched microRNAs during normal aging , 2018, Aging.

[4]  A. Jackson,et al.  Cobomarsen, an oligonucleotide inhibitor of miR‐155, co‐ordinately regulates multiple survival pathways to reduce cellular proliferation and survival in cutaneous T‐cell lymphoma , 2018, British journal of haematology.

[5]  M. Beckmann,et al.  MicroRNA in diagnosis and therapy monitoring of early-stage triple-negative breast cancer , 2018, Scientific Reports.

[6]  Ewgenij Proschak,et al.  Polypharmacology by Design: A Medicinal Chemist's Perspective on Multitargeting Compounds. , 2018, Journal of medicinal chemistry.

[7]  Christina Backes,et al.  Genome-wide MicroRNA Expression Profiles in COPD: Early Predictors for Cancer Development , 2018, Genom. Proteom. Bioinform..

[8]  Christina Backes,et al.  A high‐resolution map of the human small non‐coding transcriptome , 2018, Bioinform..

[9]  H. Dellago,et al.  Cost-utility analysis of fracture risk assessment using microRNAs compared with standard tools and no monitoring in the Austrian female population. , 2018, Bone.

[10]  J. Trojanowski,et al.  Circulating brain-enriched microRNAs as novel biomarkers for detection and differentiation of neurodegenerative diseases , 2017, Alzheimer's Research & Therapy.

[11]  L. McNamee,et al.  As Technologies for Nucleotide Therapeutics Mature, Products Emerge , 2017, Molecular therapy. Nucleic acids.

[12]  D. Bailey,et al.  Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study. , 2017, The Lancet. Oncology.

[13]  David M. Rissin,et al.  Polymerase-free measurement of microRNA-122 with single base specificity using single molecule arrays: Detection of drug-induced liver injury , 2017, PloS one.

[14]  Ruth Nussinov,et al.  A New View of Pathway-Driven Drug Resistance in Tumor Proliferation. , 2017, Trends in pharmacological sciences.

[15]  G. Calin,et al.  Non-coding RNAs: the cancer genome dark matter that matters! , 2017, Clinical chemistry and laboratory medicine.

[16]  I. P. Wijaya,et al.  Galectin-3: a novel biomarker for the prognosis of heart failure , 2017, Clujul medical.

[17]  M. Sughayer,et al.  The Bethesda System for Reporting Thyroid Cytopathology: A Meta-Analysis , 2017, Acta Cytologica.

[18]  M. Bradley,et al.  Novel bead-based platform for direct detection of unlabelled nucleic acids through Single Nucleobase Labelling. , 2016, Talanta.

[19]  T. Baum,et al.  Serum miRNA Signatures Are Indicative of Skeletal Fractures in Postmenopausal Women With and Without Type 2 Diabetes and Influence Osteogenic and Adipogenic Differentiation of Adipose Tissue–Derived Mesenchymal Stem Cells In Vitro , 2016, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[20]  E. Meiri,et al.  Multicentre validation of a microRNA-based assay for diagnosing indeterminate thyroid nodules utilising fine needle aspirate smears , 2016, Journal of Clinical Pathology.

[21]  A. Baierl,et al.  Circulating microRNA Signatures in Patients With Idiopathic and Postmenopausal Osteoporosis and Fragility Fractures. , 2016, The Journal of clinical endocrinology and metabolism.

[22]  F. Slack,et al.  The tumor-suppressive and potential therapeutic functions of miR-34a in epithelial carcinomas , 2016, Expert opinion on therapeutic targets.

[23]  I. Yaylim,et al.  Is miR‐34a a Well‐equipped Swordsman to Conquer Temple of Molecular Oncology? , 2016, Chemical biology & drug design.

[24]  P. Pietschmann,et al.  Differentially circulating miRNAs after recent osteoporotic fractures can influence osteogenic differentiation. , 2015, Bone.

[25]  E. Labourier,et al.  Molecular Testing for miRNA, mRNA, and DNA on Fine-Needle Aspiration Improves the Preoperative Diagnosis of Thyroid Nodules With Indeterminate Cytology. , 2015, The Journal of clinical endocrinology and metabolism.

[26]  Naoki Nakagawa,et al.  Anti-microRNA-21 oligonucleotides prevent Alport nephropathy progression by stimulating metabolic pathways. , 2015, The Journal of clinical investigation.

[27]  D. Haussecker.  Current issues of RNAi therapeutics delivery and development. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[28]  P. Tassone,et al.  Mir-34: A New Weapon Against Cancer? , 2014, Molecular therapy. Nucleic acids.

[29]  Hyeyoung Min,et al.  MicroRNA-targeting therapeutics for hepatitis C , 2014, Archives of pharmacal research.

[30]  F. Crawford,et al.  Plasma microRNA biomarkers for detection of mild cognitive impairment: Biomarker Validation Study , 2013, Aging.

[31]  M. Williams,et al.  Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  M. Stoffel,et al.  Miravirsen (SPC3649) can inhibit the biogenesis of miR-122 , 2013, Nucleic acids research.

[33]  A. Bouchie.  First microRNA mimic enters clinic , 2013, Nature Biotechnology.

[34]  N. Tétreault,et al.  miRNAs: their discovery, biogenesis and mechanism of action. , 2013, Clinical biochemistry.

[35]  R. Robitaille,et al.  Circulating miRNAs as sensitive and specific biomarkers for the diagnosis and monitoring of human diseases: promises and challenges. , 2013, Clinical biochemistry.

[36]  S. Kauppinen,et al.  Discovering the first microRNA-targeted drug , 2012, The Journal of cell biology.

[37]  M. Mullan,et al.  Plasma microRNA biomarkers for detection of mild cognitive impairment , 2012, Aging.

[38]  R. Aharonov,et al.  A second-generation microRNA-based assay for diagnosing tumor tissue origin. , 2012, The oncologist.

[39]  J. Burnett,et al.  RNA-based therapeutics: current progress and future prospects. , 2012, Chemistry & biology.

[40]  J. Lieberman,et al.  Special delivery: targeted therapy with small RNAs , 2011, Gene Therapy.

[41]  R. Aharonov,et al.  A second-generation microRNA-based assay for diagnosing tumor tissue origin. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  T. Fahey,et al.  Predictive Value of Cytologic Atypia in Indeterminate Thyroid Fine-Needle Aspirate Biopsies , 2011, Annals of Surgical Oncology.

[43]  R. Iyengar,et al.  Systems approaches to polypharmacology and drug discovery. , 2010, Current opinion in drug discovery & development.

[44]  Perry D Moerland,et al.  MiR423-5p As a Circulating Biomarker for Heart Failure , 2010, Circulation research.

[45]  M. Bradley,et al.  DNA analysis by dynamic chemistry. , 2010, Angewandte Chemie.

[46]  G. Yousef,et al.  MicroRNAs in clinical oncology: at the crossroads between promises and problems , 2009, Journal of Clinical Pathology.

[47]  J. Hainsworth,et al.  Introduction: unknown primary cancer. , 2009, Seminars in oncology.

[48]  A. Harris,et al.  Detection of elevated levels of tumour‐associated microRNAs in serum of patients with diffuse large B‐cell lymphoma , 2008, British journal of haematology.

[49]  R. Bernards.  Nobelprijs Fysiologie of Geneeskunde 2006 voor de ontdekking van RNA-interferentie , 2006 .

[50]  J. Castle,et al.  Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs , 2005, Nature.

[51]  C. Burge,et al.  Conserved Seed Pairing, Often Flanked by Adenosines, Indicates that Thousands of Human Genes are MicroRNA Targets , 2005, Cell.

[52]  C. Croce,et al.  Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[53]  A. Fire,et al.  Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans , 1998, Nature.

[54]  V. Ambros,et al.  The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14 , 1993, Cell.

[55]  R. D. de Boer,et al.  Galectin-3 in Heart Failure: An Update of the Last 3 Years. , 2018, Heart failure clinics.

[56]  R. Service.  Chemistry Nobel. Honors to researchers who probed atomic structure of ribosomes. , 2009, Science.

[57]  R. Bernards.  [The Nobel Prize in Physiology or Medicine for 2006 for the discovery of RNA interference]. , 2006, Nederlands tijdschrift voor geneeskunde.

[58]  G. North.  Nobel prizes: chemistry. RNA's catalytic role. , 1989, Nature.